secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0001193125-26-183710
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion reports Phase 2 COVALENT-112 positive topline: 52% C-peptide increase in early T1D
--------------------------------------------------------------------------------

- In patients diagnosed within 3 years, icovamenib 200mg QD for 12 weeks increased mean C-peptide AUC by 52% (p<0.001, n=5) at Week 12; effect sustained with ~7% decline from baseline at Week 52.
- Dose response observed; longer-standing T1D (3-15 years) preserved C-peptide through Week 52 with only modest decline.
- Company plans Phase 2 trial with extended dosing (6-12 months) plus immunosuppressant, to start H2 2026 at four U.S. academic centers.
- Study enrollment interrupted due to FDA clinical hold (resolved); data reflects about half intended population; no placebo control completed.
- Icovamenib generally well tolerated; comprehensive data to be presented at ADA Scientific Sessions in June 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000119312526183710/0001193125-26-183710-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000119312526183710/d142809d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-183710

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer